● Covered by 1 source · 1 reportMedium impact
Colossal Biosciences in talks for new funding at $20B–$30B valuation
Colossal Biosciences is negotiating to raise new capital at a valuation between $20 billion and $30 billion. The startup has begun generating revenue and has expanded its conservation technology offerings to various governments while pursuing multiple de-extinction projects.
Key points
- Colossal aims to raise new funding at $20B-$30B valuation.
- Company has started generating revenue over the past year.
- Offers conservation technology to U.S. and UAE.
- Plans to spin off artificial animal womb technology.
Funding and Valuation Update
Colossal Biosciences, known for its efforts in de-extinction, is reportedly in talks to raise new capital at a valuation of $20 billion to $30 billion. This is a significant increase from its previous valuation of $10.2 billion reported last year.
Details regarding the leading investors or the amount being raised remain unclear.
Revenue Generation
The startup has begun generating revenue over the last year, contributing to its increased valuation. Colossal co-founder and CEO Ben Lamm indicated that the company has identified three potential revenue streams.
The revenues come from its conservation technology, which has been offered to both the U.S. government and the UAE, contributing to recent investments, including a $60 million injection from the UAE.
Spin-offs and Projects
Colossal has also spun out several startups, including Breaking, Form Bio, and Astromech, focusing on diverse applications ranging from plastic breakdown to computational biology. Astromech was valued at $2 billion as of March.
Conservation Efforts
The company has expanded its de-extinction projects, recently adding the bluebuck antelope as its sixth targeted species. The Colossal Foundation is collaborating with the University of Tasmania to protect Tasmanian devils from facial cancer.
Artificial Womb Technology
Plans are underway to spin out the technology for an artificial animal womb, which has potential applications in human fertility treatments. This technology is expected to be ready by next year.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
Reporting from
Colossal Biosciences is negotiating to raise new capital at a valuation between $20 billion and $30 billion. The startup has begun generating revenue and has expanded its conservation technology offerings to various governments while pursuing multiple de-extinction projects.